
Investor Relations
Investor Relations
Corporate Profile
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
May 09
2022
2022
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
Learn More >
May 04
2022
2022
Allogene Therapeutics Reports First Quarter 2022 Financial Results
Learn More >
Apr 28
2022
2022
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
Learn More >
Apr 27
2022
2022
Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
Learn More >
Apr 27
2022
2022
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
Learn More >
Apr 14
2022
2022
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
Learn More >
Apr 13
2022
2022
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
Learn More >
Apr 12
2022
2022
Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
Learn More >
Mar 23
2022
2022
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
Learn More >
Mar 10
2022
2022